Work

Efficacy and immune activation with PEGylated human IL-10 (AM0010) in combination with an anti-PD1 in advanced NSCLC: Update

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx380.019

Authors: D.J. Wong, J.G. Schneider, R. Aljumaily, M.W. Korn, K. Autio, J.R. Infante, M.R. Patel, K. Papadopoulos, A. Naing, N. Gabrail, P. Munster, J. Goldman, P. Van Vlasselaer, A. Hung, G. Brown, M. Oft, E.B. Garon

Institutions: University of California, Los Angeles, Winthrop-University Hospital, University of Oklahoma Medical Center, University of California, San Francisco, Memorial Sloan Kettering Cancer Center, Sarah Cannon, Tennessee Oncology, Florida Cancer Specialists & Research Institute, South Texas Accelerated Research Therapeutics, The University of Texas MD Anderson Cancer Center, Gabrail Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2762834753

FWCI:

Cites:

Cited by:

Related to: 10